1.Inherited thrombophilia profile in patients with recurrent miscarriages: Experience from a tertiary care center in north India.
Narender KUMAR ; Jasmina AHLUWALIA ; Reena DAS ; Meenakshi ROHILLA ; Sunil BOSE ; Hari KISHAN ; Neelam VARMA
Obstetrics & Gynecology Science 2015;58(6):514-517
The cause of recurrent miscarriage (RM) remains unexplained in approximately 30% to 50% cases. The association of inherited thrombotic factors and RM patients has not been documented from the northern part of India. A total of 40 patients had been investigated for inherited thrombophilia workup (protein C, protein S [PS], antithrombin III, and factor V Leiden [FVL] mutation) over a period of 10 years (2005 to 2014). RM patients were divided in to three groups. Group I (only 1st trimester loss), group II (only 2nd and 3rd trimester), and group III (mixed). Each group comprised of the following numbers of patients respectively: I, 24; II, 2; III, 14. Heterozygous FVL mutation was found in 10% (4/40) cases. PS deficiency was detected in 2.7% (1/37) cases. In the present study FVL and PS were seems to be associated with a subset of patients however further studies with larger numbers of patients are recommended for better evaluation.
Abortion, Habitual*
;
Antithrombin III
;
Factor V
;
Female
;
Humans
;
India*
;
Pregnancy
;
Protein S
;
Tertiary Care Centers*
;
Tertiary Healthcare*
;
Thrombophilia*
2.The first case report of a patient with coexisting hemophilia B and Down syndrome.
Pulkit RASTOGI ; Narender KUMAR ; Jasmina AHLUWALIA ; Reena DAS ; Inusha PANIGRAHI
Blood Research 2017;52(1):75-76
No abstract available.
Down Syndrome*
;
Hemophilia A*
;
Hemophilia B*
;
Humans
3. Biotechnological intervention in betelvine (Piper betle L.): A review on recent advances and future prospects
Suryasnata DAS ; Reena PARIDA ; Reena SRIRAM SANDEEP ; Sanghamitra NAYAK ; Sujata MOHANTY
Asian Pacific Journal of Tropical Medicine 2016;9(10):938-946
Betelvine (Piper betle L.) is cultivated for its deep green heart shaped leaf for (15–20) million Indian and 2 billion foreign consumers annually. The crop provides Rs (6 000–7 000) million of national income per year and at the same time leaves worth Rs (30–40) million is exported to other countries. The leaves are not only used directly for chewing purposes but also possesses antioxidant, anti-inflammatory, anti-apoptotic, anti-cancer and anti-microbial properties. Besides, the leaves also contain eugenol rich essential oil (1%–3%) which is the source for medicine, stimulant, antiseptic, tonic and other ayurvedic formulations. The essential oil also contains chavibetol, caryophyllene and methyl eugenol which are the potent source for preparation in ayurvedic medicine and herbal products. Cost of betelvine essential oil is 10$ per 5 mL. In spite of its great economical and medicinal importance betelvine is still neglected by the researchers for proper characterization and authentication for selection of elite landraces. Lack of awareness among people, use of same planting material for many generations, existing of many synonyms for a single landraces, no proper characterization of available landraces are some of the significant constraints for its commercialization. Our review endeavours a complete advance in the research on betelvine, existing lacunae for its proper characterization and commercial cultivation. It also attempts to provide a comprehensive account on biotechnological interventions made in betelvine aimed at complementing conventional programmes for improvement of this nutraceutically important cash crop.
4.Plasma cell leukemia in North India: retrospective analysis of a distinct clinicohematological entity from a tertiary care center and review of literature.
Karthik BOMMANNAN ; Man Updesh Singh SACHDEVA ; Pankaj MALHOTRA ; Narender KUMAR ; Prashant SHARMA ; Shano NASEEM ; Jasmina AHLUWALIA ; Reena DAS ; Neelam VARMA ; Gaurav PRAKASH ; Alka KHADWAL ; Radhika SRINIVASAN ; Subhash VARMA
Blood Research 2016;51(1):23-30
BACKGROUND: Plasma cell leukemia (PCL) is a rare and aggressive plasma cell neoplasm. In PCL, clonal plasma cells comprise ≥20% of the peripheral blood (PB) leukocytes and/or the absolute clonal PB plasma cell count is ≥2×10(9)/L. Primary PCL (PPCL) originates de novo, whereas, secondary PCL (SPCL) evolves from pre-existing multiple myeloma. METHODS: Clinicohematological features, immunophenotypic profile, and survival of PCL patients were analyzed retrospectively. RESULTS: Between January 2007 and December 2014, ten PPCL and four SPCL patients were investigated (8 PPCLs and 3 SPCLs had complete clinical data). All were North Indians, sharing common geography and ethnicity. Our cohort showed less frequent renal failure, more frequent hepatomegaly, and non-secretory type disease. In contrast to western literature, flow cytometric immunophenotyping of our cohort revealed altered expression of CD138 (67%), CD56 (33%), and CD20 (0%). With novel therapeutic agents, these PPCL patients had a median overall survival of 15 months. CONCLUSION: We highlight that our PPCL patients from North India had distinct clinicohematological and immunophenotypic profiles. The significance of our findings must be tested in a larger patient cohort and must be supported by molecular and cytogenetic investigations to unmask possible significant effects on pathogenesis.
Cohort Studies
;
Cytogenetics
;
Geography
;
Hepatomegaly
;
Humans
;
Immunophenotyping
;
India*
;
Leukemia, Plasma Cell*
;
Leukocytes
;
Multiple Myeloma
;
Neoplasms, Plasma Cell
;
Plasma Cells*
;
Plasma*
;
Renal Insufficiency
;
Retrospective Studies*
;
Tertiary Care Centers*
;
Tertiary Healthcare*